L-Methylfolate Treatment for Optic Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for optic disorders such as optic neuropathy, retinopathy, and macular degeneration are inadequate, particularly for individuals with malfunctions in the folate and BH4 cycles, and excessive folic acid intake can be detrimental, leading to insufficient metabolically active folate and related metabolic issues.
Innovation Solution
Administering downstream folate compounds like L-methylfolate, optionally with methylcobalamin, vitamin B6, and vitamin D3, while reducing folic acid intake, to improve visual acuity and alleviate symptoms in non-folic acid-deficient subjects with malfunctions in the folate and BH4 cycles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If folic acid supplementation is administered to treat optic neuropathy, then visual improvement is achieved in folic acid-deficient patients, but visual acuity may worsen in non-folic acid-deficient patients due to insufficient conversion to metabolically active forms
Solution Approach 1:
The patent applies local quality by providing different folate formulations tailored to specific patient needs: reduced folic acid for non-deficient patients and active metabolites (L-methylfolate, folinic acid) for patients with conversion deficiencies. This personalized approach ensures each patient receives the appropriate form of folate based on their metabolic capacity, preventing harm while maintaining treatment effectiveness.
Solution Approach 2:
The patent changes the chemical parameter of folate administration from passive folic acid to active metabolites (L-methylfolate, folinic acid). This parameter change bypasses the need for enzymatic conversion, directly providing metabolically active forms that can be utilized by all patients regardless of their MTHFR or other enzyme functionality, thereby eliminating the risk of visual deterioration.
2Quantity of substance
If high doses of folic acid are administered, then nutrient supplementation is provided, but absorption and conversion to active forms become insufficient, leading to metabolic issues
Solution Approach 1:
The patent applies preliminary action by providing folate in its already-activated forms (L-methylfolate, folinic acid) rather than requiring the body to convert folic acid. This pre-conversion eliminates the bottleneck at the enzymatic conversion step, ensuring that sufficient active folate is available immediately without relying on potentially deficient conversion pathways.
Solution Approach 2:
The patent uses L-methylfolate and folinic acid as intermediary compounds that bridge the gap between dietary folate intake and cellular utilization. These intermediaries are directly absorbable and bypass the problematic conversion steps, serving as effective mediators that ensure reliable folate delivery to tissues regardless of enzymatic functionality.
3Reliability
If downstream folate compounds are administered to non-folic acid-deficient patients, then visual acuity improves, but treatment complexity increases compared to simple folic acid supplementation
Solution Approach 1:
The patent inverts the conventional approach by not starting with folic acid and hoping for conversion, but rather starting with the end product (active folate metabolites) and working backward. This inversion eliminates the need for complex conversion pathways and diagnostic workup to determine conversion capacity, simplifying the treatment logic while maintaining efficacy.
Data Source
AI summary
The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream folate compounds and/or methyl-B12. In one particular embodiment, the method comprises administration of L-methylfolate. In other embodiments, the method involves administering both L-methylfolate and methyl-B12. In still further embodiments, the method further involves reducing dietary intake of folic acid. In certain embodiments, the method further involves identifying a subject organism with a malfunction in one or more of the folate or B4 cycles. In certain embodiments, such a malfunction is one or more of the C677T and A1298C mutations. In still further embodiments, the method further involves identifying a subject organism that is deficient in vitamins B-12 and D3 but which possesses excess homocysteine.